<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728296</url>
  </required_header>
  <id_info>
    <org_study_id>islet body-01</org_study_id>
    <nct_id>NCT03728296</nct_id>
  </id_info>
  <brief_title>A Study of Autologous Induced Islet Body With Type 1 Diabetes</brief_title>
  <official_title>Clinical Study on the Safety and Efficacy of Autologous Induced Islet Body With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allife Medical Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allife Medical Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre、single arm、open-label study，to investigate the safety and efficacy of&#xD;
      Autologous induced islet body With Type 1 diabetes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>islet body treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>islet body</intervention_name>
    <description>Transplanting islet bodies under the diaphragm</description>
    <arm_group_label>islet body treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 to 70 years old (including 18 and 70 years old)&#xD;
&#xD;
          2. Diagnosed as type I diabetes, the diagnostic criteria refer to the 1990 WHO diabetes&#xD;
             diagnostic criteria:&#xD;
&#xD;
        （1）Diabetes symptoms (hyperglycemia caused by polydipsia, polyphagia, weight loss, itchy&#xD;
        skin, blurred vision and other acute metabolic disorders) + random blood glucose ≥ 11.1nmol&#xD;
        / L; （2）Fasting blood glucose ≥7.0mmol/L or 75g glucose meets 2-hour blood glucose&#xD;
        ≥11.1mmol/L.&#xD;
&#xD;
        3、Voluntary informed consent is given, agree to follow the trial treatment and visit plan.&#xD;
&#xD;
        Note: 2 is the venous plasma glucose level, if there is no diabetes symptoms, it is&#xD;
        necessary to repeat the test on the next day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute complications of diabetes: including diabetic ketosis, diabetic&#xD;
             ketoacidosis, diabetes, hyperglycemia, hypertonic state, etc.&#xD;
&#xD;
          2. Patients with Severe bacterial and viral infections&#xD;
&#xD;
          3. patients are participating in other clinical trials and treating with other immune&#xD;
             cellular products (DC, CIK, T, NK, and Car T products with CD19 or other targets)&#xD;
&#xD;
          4. Patients with severe cardiovascular and cerebrovascular disease (NYHA class 3-4)&#xD;
             cannot cooperate with the study&#xD;
&#xD;
          5. Patients with severe liver dysfunction(liver function AST and ALT exceeded 2.5 times&#xD;
             the normal upper limit).&#xD;
&#xD;
          6. Patients with kidney disease or moderate to severe renal insufficiency (renal function&#xD;
             eGFR &lt;60 ml/min/1.73 m2)&#xD;
&#xD;
          7. Women in pregnancy (urine/blood pregnancy test positive) or lactation; men or women&#xD;
             with pregnancy plans in the last year; patients are not guaranteed to take effective&#xD;
             contraceptive measures during the trial;&#xD;
&#xD;
          8. patients were diagnosed as tumor or tumor chemotherapy, radiotherapy and acute uric&#xD;
             acid nephropathy within 5 years.&#xD;
&#xD;
          9. Other circumstances that researchers do not consider suitable for research.&#xD;
&#xD;
         10. Withdrawal from trial, loss of follow-up or death due to other reasons&#xD;
&#xD;
         11. Incomplete data, affecting effectiveness and safety judges&#xD;
&#xD;
         12. Researchers believe that the need for termination of the trial is needed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

